Jeremy B Green

US Patent:

6528509, Mar 4, 2003

Filed:

Oct 5, 2001

Appl. No.:

09/972437

Inventors:

Michael Hale - Bedford MA
Xiaoling Xie - Cambridge MA
Jeremy Green - Burlington MA
Jingrong Cao - Newton MA
Christopher Baker - Bedford MA
Francois Maltais - Somerville MA
James Janetka - Beverly MA
Guy Bemis - Arlington MA
Michael Mullican - Needham MA
Judith Straub - Cambridge MA
Qing Tang - Cambridge MA
Robert Mashal - West Newton MA

Assignee:

Vertex Pharmacuticals, Incorporated - Cambridge MA

International Classification:

A61K 315377

US Classification:

5142365, 540575, 544140, 544295, 544328, 544367, 544371, 544363, 546 86, 546146, 546199, 5462737, 5462754, 546211, 548127, 5483124, 5483641, 5483644, 5483657

Abstract:

Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

US Patent:

6593357, Jul 15, 2003

Filed:

Aug 22, 2002

Appl. No.:

10/225719

Inventors:

Jeremy Green - Burlington MA
Jingrong Cao - Newton MA
Michael Hale - Bedford MA
Christopher Baker - Bedford MA
Francois Maltais - Somerville MA
James Janetka - Beverly MA
Michael Mullican - Needham MA
Guy Bemis - Arlington MA
Xiaoling Xie - Cambridge MA
Judith Straub - Cambridge MA
Qing Tang - Cambridge MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 314155

US Classification:

514406, 544328, 5462754, 546211, 5483641, 5483644, 5483657, 548127, 5483117, 5483127

Abstract:

Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

US Patent:

6642227, Nov 4, 2003

Filed:

Apr 10, 2002

Appl. No.:

10/121035

Inventors:

Jingrong Cao - Newton MA
Jeremy Green - Burlington MA
Young-Choon Moon - Lexington MA
Jian Wang - Boston MA
Mark Ledeboer - Acton MA
Edmund Harrington - South Boston MA
Huai Gao - Natick MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C07D40904

US Classification:

5142278, 5142358, 51425219, 514275, 544 60, 544122, 544331

Abstract:

The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative o thereof, wherein A, B, R , R , R , R , and R are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

US Patent:

6653300, Nov 25, 2003

Filed:

Dec 19, 2001

Appl. No.:

10/026975

Inventors:

David Bebbington - Newbury, GB
Jean-Damien Charrier - Wantage, GB
Julian Golec - Swindon, GB
Jeremy Green - Burlington MA
David Kay - Purton, GB
Ronald Knegtel - Abingdon, GB
Andrew Miller - Didcot, GB
Ronald Tomlison - Marlborough MA
Pan Li - Arlington MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 3133

US Classification:

514183, 5142641, 5142661, 51426623, 5142664, 514403, 514269, 514274, 544253, 544283, 544286, 544296, 544298, 544315, 544322, 544326, 544333, 5483561, 5483541, 5483647, 5483714

Abstract:

This invention describes novel pyrazole compounds of formula Iâ: wherein Qâ is âOâ, âC(R ) â, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclopropanediyl, and R is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R and R are independently selected from TâR or LâZâR , or R and R are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R and R are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimers disease.

US Patent:

6693108, Feb 17, 2004

Filed:

Feb 12, 2002

Appl. No.:

10/074177

Inventors:

Jeremy Green - Burlington MA
Guy Bemis - Arlington MA
Anne-Laure Grillot - Cambridge MA
Mark Ledeboer - Acton MA
Francesco G. Salituro - Marlboro MA
Edmund Harrington - South Boston MA
Huai Gao - Natick MA
Christopher Baker - Bedford MA
Jingrong Cao - Newton MA
Michael Hale - Bedford MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C07D40104

US Classification:

514275, 544331

Abstract:

The present invention provides compounds of formula I: where R is H, CONH , T âR, or T âAr , n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

US Patent:

6699865, Mar 2, 2004

Filed:

Jan 2, 2003

Appl. No.:

10/335793

Inventors:

Michael Hale - Bedford MA
Xiaoling Xie - Cambridge MA
Jeremy Green - Burlington MA
Jingrong Cao - Newton MA
Christopher Baker - Bedford MA
Francois Maltais - Somerville MA
James Janetka - Beverly MA
Guy Bemis - Arlington MA
Michael Mullican - Needham MA
Judith Straub - Cambridge MA
Qing Tang - Cambridge MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 314155

US Classification:

5142365, 540575, 544140, 544295, 544363, 544371, 546146, 546199, 546211, 546 86, 5483641

Abstract:

Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

US Patent:

6743791, Jun 1, 2004

Filed:

Feb 8, 2002

Appl. No.:

10/071699

Inventors:

Jingrong Cao - Newton MA
Jeremy Green - Burlington MA
Michael Hale - Bedford MA
Francois Maltais - Tewksbury MA
Judy Straub - Cambridge MA
Qing Tang - Cambridge MA
Alex Aronov - Watertown MA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C07D40304

US Classification:

5142358, 51426622, 514275, 544122, 544284, 544331

Abstract:

Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z and Z are each independently nitrogen or CH and Ring A, T R , QR , U R , and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

US Patent:

6916798, Jul 12, 2005

Filed:

Aug 2, 2002

Appl. No.:

10/212471

Inventors:

Jeremy Green - Burlington MA, US
Michael J. Arnost - North Andover MA, US
Albert Pierce - Cambridge MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K031/4152
A61K031/655
C07D231/08
C07D231/20
C07D401/02

US Classification:

514150, 514407, 534753, 534769, 534774, 534775, 5483641, 5483644, 5483647, 5483651, 5483657

Abstract:

The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.